Iqvia 3Q Profit, Rev Rise on Higher Demand

Dow Jones

2025/10/28

By Rob Curran

Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.

The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier.

Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet.

Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion.

IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share.

IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

October 28, 2025 07:50 ET (11:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2578956596"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578956596\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578956596?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578956596","market":"hk","top_or_hot":-1,"title":"Iqvia 3Q Profit, Rev Rise on Higher Demand","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n</p>\n<p>\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n</p>\n<p>\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n</p>\n<p>\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iqvia 3Q Profit, Rev Rise on Higher Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIqvia 3Q Profit, Rev Rise on Higher Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-28 19:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n</p>\n<p>\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n</p>\n<p>\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n</p>\n<p>\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791710400.SGD","symbol_name":"Fidelity Global Demographics A-ACC-SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578956596","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578956596","pubTimestamp":1761652200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier.Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet.Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion.IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share.IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK4585":"ETF&股票定投概念","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","BK4530":"医药外包概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4588":"碎股","IQV":"艾昆纬","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4121":"生命科学工具和服务","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)"},"translate_title":"Iqvia第三季度利润、营业额因需求增加而上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n\n\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n\n\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n\n\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n\n\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n\n\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 07:50 ET (11:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}